PFE

Pfizer Inc
NYSEHEALTHCAREDRUG MANUFACTURERS - GENERAL

Key Statistics

Market Cap
$164.67B
P/E Ratio
41.27
EPS
$0.70
Beta
0.30
52W High
$30.99
52W Low
$22.76
50-Day MA
$28.80
200-Day MA
$26.98
Dividend Yield
7.46%
Profit Margin
6.34%
Forward P/E
9.71
PEG Ratio
8.83

About Pfizer Inc

Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered on 42nd Street in Manhattan, New York City. The name of the company commemorates its co-founder, Charles Pfizer (1824-1906). Pfizer develops and produces medicines and vaccines for immunology, oncology, cardiology, endocrinology, and neurology. The company has several blockbuster drugs or products that each generate more than 1 billion USD in annual revenues.

Official WebsiteUSAFY End: December

Fundamentals

Revenue (TTM)$63.62B
Gross Profit (TTM)$47.65B
EBITDA$24.94B
Operating Margin29.10%
Return on Equity4.47%
Return on Assets5.59%
Revenue/Share (TTM)$11.17
Book Value$15.61
Price-to-Book1.85
Price-to-Sales (TTM)2.59
EV/Revenue3.349
EV/EBITDA15.82
Quarterly Earnings Growth (YoY)-9.70%
Quarterly Revenue Growth (YoY)-0.40%
Shares Outstanding$5.70B
Float$5.69B
% Insiders0.26%
% Institutions69.27%

Historical Volatility

HV 10-Day
26.16%
HV 20-Day
24.63%
HV 30-Day
23.37%
HV 60-Day
19.85%
HV Rank
76.6%

Volatility is currently expanding

Analyst Ratings

Consensus ($30.22 target)
1
Strong Buy
8
Buy
17
Hold
1
Sell
1
Strong Sell

Latest News

Pfizer: $1.5bn Of Blackstone Funding Doesn't Make Berobenatide A Winning Obesity Drug

Pfizer partners with Blackstone, securing up to $1.5bn in funding for berobenatide, a potential first-in-class monthly GLP-1 agonist for obesity. PFE faces stagnant revenues, heavy debt, and looming patent expiries on key drugs, making GLP-1 success critical for future growth. Berobenatide offers monthly dosing and potential manufacturing cost advantages, but safety and efficacy data have notable gaps versus established competitors.

Seeking Alpha11/12/2026Positive
Pfizer and Blackstone Life Sciences Announce Strategic Funding Agreement for Obesity Program

NEW YORK & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Blackstone Life Sciences (“Blackstone”) today announced a strategic co-funding agreement under which funds managed by Blackstone will pay up to a total of $1.5 billion of development costs through 2028 for berobenatide, an investigational, potential first-in-class monthly GLP-1 receptor agonist peptide being studied for chronic weight management and obesity-related conditions. In exchange for the funding, Blackstone will.

Business Wire11/11/2026Neutral

Turn research into an automated options-selling system

Tiblio connects your broker and runs your put-and-call-writing strategy for you — on PFE and any ticker you trade — then tracks every position and per-strategy win rate.

See how it works

More HEALTHCARE Stocks

Data last updated: 11/16/2026